Indaptus Therapeutics, Inc. (NASDAQ:INDP) Short Interest Update

Indaptus Therapeutics, Inc. (NASDAQ:INDP) was the recipient of a significant growth in short interest during the month of December. As of December 15th, there was short interest totaling 17,701 shares, a growth of 25.9% from the November 30th total of 14,057 shares. Based on an average daily trading volume, of 39,649 shares, the days-to-cover ratio is presently 0.4 days. Currently, 1.3% of the company’s shares are sold short. Currently, 1.3% of the company’s shares are sold short. Based on an average daily trading volume, of 39,649 shares, the days-to-cover ratio is presently 0.4 days.

Wall Street Analyst Weigh In

Several equities research analysts recently weighed in on INDP shares. Wall Street Zen cut Indaptus Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, December 6th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Indaptus Therapeutics in a research report on Wednesday, October 8th. One equities research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, Indaptus Therapeutics presently has an average rating of “Sell”.

Indaptus Therapeutics Price Performance

NASDAQ INDP opened at $2.72 on Wednesday. Indaptus Therapeutics has a 1 year low of $1.65 and a 1 year high of $47.60. The stock has a market capitalization of $4.76 million, a PE ratio of -0.09 and a beta of 1.02. The business’s 50-day moving average is $2.55 and its 200 day moving average is $5.48.

Indaptus Therapeutics (NASDAQ:INDP) last released its quarterly earnings data on Wednesday, November 12th. The company reported ($2.98) earnings per share for the quarter, topping the consensus estimate of ($4.17) by $1.19. As a group, equities research analysts anticipate that Indaptus Therapeutics will post -1.79 earnings per share for the current year.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC acquired a new position in Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor acquired 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 1.72% of Indaptus Therapeutics at the end of the most recent quarter. 7.06% of the stock is owned by hedge funds and other institutional investors.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.